Stockscreener 앱 받기
2.60
0.19%
0.005
Alpha Tau Medical Ltd 주식(DRTS)의 최신 뉴스
Alpha Tau Medical’s (DRTS) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Lifts Earnings Estimates for Alpha Tau Medical - Defense World
Latham & Watkins Advises Alpha Tau Medical in US$36.9 Million Registered Direct Offering - Latham & Watkins LLP
Alpha Tau Medical Ltd: Strategic Investment and Promising Clinical Milestones Drive Buy Rating - TipRanks
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Medical (DRTS) Secures $36.9M in Strategic Stock Sale - GuruFocus
Oramed Invests in Alpha Tau (DRTS) with Strategic Partnership | - GuruFocus
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Completes $36.9 Million Strategic Investment in Alpha Tau Medical - marketscreener.com
Alpha Tau enters strategic marketing alliance with Oramed - TipRanks
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Alpha Tau's $37M Deal Unlocks Major Growth: 4 US Trials and Marketing Alliance Signal Expansion - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals - Yahoo Finance
Alpha Tau Medical (NASDAQ:DRTSW) Shares Up 2.3% – Still a Buy? - Defense World
Comparing ICU Medical (NASDAQ:ICUI) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
High Intensity Focused Ultrasound (HIFU) Market to Witness - openPR.com
Alpha Emitter Market to Witness Massive Growth by 2032 | Actinium - openPR.com
FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer - Curetoday
Alpha Tau Medical (NASDAQ:DRTSW) Shares Down 7.4% – Time to Sell? - Defense World
Alpha Tau Receives Fda Approval to Initiate A Trial for Patients with Recurrent Glioblastoma - MarketScreener
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM - TipRanks
Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma - MarketScreener
Alpha Tau Medical Receives FDA Approval for Glioblastoma Trial - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma - GlobeNewswire
Major FDA Approval: Alpha Tau's Revolutionary Brain Cancer Treatment Advances to Human Trials - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Comprehensive Insights of the Global Vulvar Cancer Market: Key Drivers, Trends, Growth Opportunities, and F... - WhaTech
Pancreatic Ductal Adenocarcinoma Pipeline: Shaping the Future - openPR.com
Alpha Emitter Market Demand, Growth and Future Scope 2025-2032 | - openPR
HC Wainwright Forecasts Lower Earnings for Alpha Tau Medical - Defense World
Pancreatic Cancer Clinical Pipeline | 290+ Companies Advancing the Future of Treatment - openPR.com
Alpha Tau Medical’s (DRTS) Buy Rating Reaffirmed at HC Wainwright - Defense World
Q1 Virtual Investor Summit: On-Demand Presentations Now Live - The Globe and Mail
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target - Investing.com
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target By Investing.com - Investing.com UK
Promising Clinical and Regulatory Milestones Drive Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges - TipRanks
Alpha Tau Medical Reports 2024 Earnings and Clinical Progress - TipRanks
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 2.7% – Time to Sell? - Defense World
Alpha Tau Medical Reports 2024 Financial Results and Advances in Cancer Therapy Trials - TipRanks
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau's Cancer Therapy Achieves 100% Disease Control Rate in Latest Trials - StockTitan
Alpha Emitter Market to Witness Remarkable Growth with Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd - openPR
U.S. Brain Tumor Market Size & Share | Industry Report 2034 - Grand View Research
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences - TipRanks
Alpha Tau to Participate in March Investor Conferences - The Manila Times
Sonodynamic Therapy Shows Promise for Glioblastoma Treatment - Targeted Oncology
Alpha Tau Achieves MDSAP Certification, Boosting Global Expansion Efforts - TipRanks
0.39%
3.66%
자본화:
|
볼륨(24시간):